Presented by:

	Kasey Bamel, DNP, FNP-BC, AOCNP UC San Diego Moores Cancer Center
	Van Hilburn, PharmD, BCOP, MBA UC San Diego Moores Cancer Center
	Sandip P. Patel, MD UC San Diego Moores Cancer Center

Learning Objectives:
Following this activity, participants should be able to:

• Identify patients with resectable non-small cell lung cancer (NSCLC) who may be eligible for neoadjuvant or adjuvant systemic therapy.
• Recognize the different types of neoadjuvant and adjuvant systemic therapy regimens available for treating resectable NSCLC.
• Review the adverse events that may occur in patients with resectable NSCLC who receive the new neoadjuvant and adjuvant systemic therapy regimens.

Fee Information:
There is no fee to attend this activity.

Accreditation:
CE credit for this activity is available for the oncology care team including physicians, nurses, pharmacists, PAs, and case managers.

Upcoming Tumor Board Webinar:

• Friday, May 23 | Multiple Myeloma
   

Recorded Presentations: 
Access recorded presentations from this series.

Supporters:
This activity is supported by educational grants from AstraZeneca; Coherus BioSciences; Eisai Inc.; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis; and Sanofi. This activity is supported by independent educational grants from Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA. This is activity is supported by independent medical education grants from AbbVie and GSK.